Figure 6.

ICOS Agonist Targeted to the Tumor Enhances Lymphocyte Tumor Infiltration

(A) Treatment schedule of B16-MRP1 tumor-bearing mice. (B) Immunofluorescence imaging of tumors stained with CD3, CD8, CD4, and B220 antibodies. (C) CD3⁺, CD8⁺, CD4⁺, and B220 infiltration in treated B16-MRP1 tumors. It is represented as the relative area of stained cell over the whole tumor slide. Data are expressed as the mean ± SEM. (D) Percentage of CD8⁺ cells of the whole CD45⁺ fraction of cells that infiltrates each tumor, quantified by flow cytometry (five mice per group of control, VAX, and VAX with CTLA-4 Ab treatment; eight mice per group of MRP1-ICOS aptamer, anti-CTLA-4 antibody, and VAX combination treatment). Data are expressed as the mean ± SEM. *p < 0.05, **p < 0.01.